clinical trial · NCT06675955
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Hoffmann-La Roche·phase3·recruiting·n = 500
Multiple SclerosisOcrelizumab
brief summary
The study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab. From Protocol Version 6 onwards, treatment within this study will be limited to the currently approved doses of ocrelizumab, 600 milligrams (mg), intravenous (IV) infusion or 920 mg, subcutaneous (SC) injection.
started
Dec 13, 2024
primary completion
Dec 31, 2029
completion
Dec 31, 2029
last updated
Feb 18, 2026
official title
An Open-label, Multicenter Extension Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Ocrelizumab in Patients With Multiple Sclerosis Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study and Without Access to a Post-trial Access Program
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol